ArticlePharmaceutics2023

Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA.

Francisco José Toja-Camba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.